179420-79-2

Upstream product

• 179420-77-0 ethyl 4-(3-bromophenyl)-3,4,5,6-tetrahydro-2H-pyran-4-carboxylic acid 
• 624-92-0 Dimethyldisulphide 
• 179420-76-9 ethyl 4-(3-bromophenyl)-3,4,5,6-tetrahydro-2H-pyran-4-carboxylate 
• 14062-30-7 ethyl 2-(3-bromophenyl)acetate 

Downstream Products

• 179420-80-5 4-(3-methylsulfanyl-phenyl)-tetrahydro-pyran-4-carboxylic acid methyl ester 
• 179420-81-6 methyl 4-(3-mercaptophenyl)-3,4,5,6-tetrahydro-2H-pyran-4-carboxylate 
• 179420-78-1 methyl 4-(3-methylsulfinylphenyl)-3,4,5,6-tetrahydro-2H-pyran-4-carboxylate 
• 179420-54-3 4-{3-[4-(2-methyl-1H-imidazol-1-yl)phenylthio]phenyl}-3,4,5,6-tetrahydro-2H-pyran-4-carboxylic acid 
• 179420-53-2 ethyl 4-{3-[4-(2-methyl-1H-imidazol-1-yl)phenylthio]phenyl}-3,4,5,6-tetrahydro-2H-pyran-4-carboxylate 
• 179420-17-8 4-[3-[4-(2-methylimidazol-1-yl)phenylthio]phenyl]-3,4,5,6-tetrahydro-2H-pyran-4-carboxamide 

Relevant academic research and scientific papers

Optimization of imidazole 5-lipoxygenase inhibitors and selection and synthesis of a development candidate

Structural modification of imidazole 5-lipoxygenase (5-LO) inhibitors for optimizing inhibitory potency, pharmacokinetic behavior and toxicity (ocular) profile led to 4-{3-[4-(2-methyl-1H-imidazol-1-yl)phenylthio]}phenyl-3,4,5,6- tetrahydro-2H-pyran-4-car